This year, the Elias Tillandz prize for the best scientific paper published in 2019 in BioCity Turku has been awarded to Academician Sirpa Jalkanen and her research group.
The Cancer Drug Resistance laboratory is looking for two doctoral candidates to join a new and exciting research group in the University of Turku, Turku, Finland.
Glucocorticoids, which are widely used as treatment in intensive care, can nearly quadruple the death rate of patients suffering from acute respiratory distress syndrome. Researchers at the University of Turku, Finland, discovered the reason for the higher mortality. The findings are also important in the fight against COVID-19 disease.
Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program. With a total funding of 10 million euros, Cancer IO is a significant IO focused Nordic research and innovation program.
New study from researchers in Finland and the United Kingdom reveals that tumors lacking a protein called BAP1 have an ineffective immune reaction against cancer, thus rendering immunotherapies ineffectual, particularly in uveal melanomas (UM). The researchers also discovered that when BAP1 is lost, other molecules will be present in order to support cancer growth. Luckily, some of these molecules can be targeted with existing drugs, which can lead to the development of novel immunotherapies.
Researchers from the University of Turku have discovered a new route that transports subcutaneously administered antibodies into lymph nodes in just a few seconds. The discovery enables targeted therapies for the immune system.
Contrary to prior belief, the white blood cells enter the spleen primarily via vessels in the red pulp. The research results change thoroughly our perception of the spleen producing antibodies vital for the human body.